Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Here are details of Memo Therapeutics‘ latest funding round :
🚀 Launch
2012
🏭 Industry
Biotechnology
🧠Management
Erik Van Den Berg (CEO), Christoph Esslinger (CSO), Jürgen Beck (CMO), Lars Spenger (CFO)
💸 Funding & Investors
| INVESTMENT (Novembre 2023) | €26 million (Series C) |
| INVESTORS (Novembre 2023) | led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures and Red Alpine joined in the round. |
🎯 Funding purpose
Complete U.S. Phase II clinical development of its best- and first-in-class antibody, AntiBKV, intended to neutralize BK polyomavirus (“BKV”) infection in kidney transplant recipients.
🌐 Country HQ
Switzerland (Zurich)